Tocilizumab for the treatment of systemic juvenile idiopathic arthritis

  • Technology appraisal guidance
  • TA238
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

June 2024: The wording of the recommendation describing the commercial arrangement (see section 1.1), and in section 2.3, was updated to include procurement information about tocilizumab biosimilars.

ISBN: 978-1-4731-6169-6